<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The neuroprotective effects of a systemically active, potent, group II selective metabotropic <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>, LY354740, was assessed in the middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>LY354740 (0.3, 3.0 or 30.0 mg/kg) was administered subcutaneously (s.c.) 30 min prior to and 3 hours after the induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty four hours after the ischaemic insult, the brains were processed for the evaluation of <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes </plain></SENT>
<SENT sid="3" pm="."><plain>No significant reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes were observed in treated animals at any of the doses investigated </plain></SENT>
<SENT sid="4" pm="."><plain>These data provide no support for the view that group II metabotropic <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptors have a major influence on ischaemic damage in this model </plain></SENT>
</text></document>